Testing the Addition of Anti-Cancer Drug, Cetuximab, to Standard of Care Treatment (Pembrolizumab) for Returning or Spreading Head and Neck Cancer After Previous Treatment
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Seagen Inc.
Johnson & Johnson Enterprise Innovation Inc.
Merck Sharp & Dohme LLC
Eastern Cooperative Oncology Group
NRG Oncology
Eastern Cooperative Oncology Group
R-Pharm
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Radiation Therapy Oncology Group
Incyte Corporation
Bristol-Myers Squibb
Azienda USL Reggio Emilia - IRCCS
Pfizer
Merck Sharp & Dohme LLC
Groupe Oncologie Radiotherapie Tete et Cou
Groupe Oncologie Radiotherapie Tete et Cou
Ludwig-Maximilians - University of Munich
AVEO Pharmaceuticals, Inc.
Mirati Therapeutics Inc.
Alliance for Clinical Trials in Oncology
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Merck Sharp & Dohme LLC
Gustave Roussy, Cancer Campus, Grand Paris
Pfizer
Bristol-Myers Squibb
Canadian Cancer Trials Group
Sun Yat-sen University
Merck Sharp & Dohme LLC
Sixth Affiliated Hospital, Sun Yat-sen University
SWOG Cancer Research Network
Cinnagen
Trans Tasman Radiation Oncology Group
Bristol-Myers Squibb
Amgen
Radiation Therapy Oncology Group
Radiation Therapy Oncology Group
Radiation Therapy Oncology Group
ChineseAMS
Bristol-Myers Squibb
Federation Francophone de Cancerologie Digestive
Swiss Cancer Institute
Lund University Hospital
Fudan University
Fudan University
National Cancer Institute (NCI)
Alliance for Clinical Trials in Oncology
Groupe Oncologie Radiotherapie Tete et Cou
Catholic University of the Sacred Heart
Merck KGaA, Darmstadt, Germany